FiberSense plans professional-care expansion for CE-marked CGM

FiberSense AG said it is preparing a regulatory update to expand its CE-marked continuous glucose monitoring system into selected hospital and professional healthcare settings. The company is targeting completion of the regulatory work in the first half of 2027 as it broadens its optical sensing strategy beyond personal diabetes care.

Why it matters: - FiberSense is trying to move its CE-marked glucose monitor from personal use into professional healthcare settings. - The shift could make continuous glucose data and reusable components more relevant in hospitals and clinical workflows. - The move also signals a broader push by FiberSense toward continuous multi-analyte monitoring beyond glucose.

What happened: - FiberSense AG said it plans to expand the clinical application of its new Continuous Glucose Monitoring System into selected professional healthcare settings. - The company is preparing a regulatory update to the system’s intended use to include selected hospital and professional healthcare settings. - FiberSense is targeting completion of the planned regulatory activities in the first half of 2027. - The announcement follows CE marking for the FiberSense CGM System in June. - FiberSense is headquartered in Basel, Switzerland.

The details: - The FiberSense CGM System combines continuous glucose monitoring with a sensor and overtape designed for up to 28 days of use. - The system also uses a removable and rechargeable detector unit. - The planned move into professional care is meant to support FiberSense’s broader medical strategy. - FiberSense said the strategy is focused on settings where continuous glucose data, reduced handling burden and reusable components may be relevant. - The company’s underlying optical sensing technology has potential uses beyond CGM. - Ketones, lactate and cortisol are among the next targets under evaluation for continuous multi-analyte monitoring. - FiberSense said the planned professional-care expansion remains subject to applicable regulatory, quality, clinical, commercial and market-specific requirements.

Between the lines: - The company is positioning optical sensing as a platform technology, not just a diabetes product. - A professional-care update could broaden the commercial case for FiberSense if the company clears regulatory and market hurdles. - The focus on reusable hardware and long-wear sensors suggests an effort to reduce workflow friction in care settings. - The forward-looking language also shows the company is still in the planning phase, not a commercial rollout.

What's next: - FiberSense expects to finish the regulatory activities tied to the intended-use update in H1 2027. - Any future professional-care application or market expansion will depend on regulatory, quality, clinical, manufacturing, commercial, notified body and market-specific requirements. - The company said future applications beyond glucose also remain subject to those requirements. - More information is available in FiberSense’s LinkedIn page.

The bottom line: - FiberSense is using its CE-marked CGM as a launchpad for a wider professional-care and multi-biomarker strategy.